Skip to main
MGX

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Therapeutics Inc. has developed a comprehensive genome editing toolbox that supports both small and large-scale genomic alterations, positioning the company favorably within the genetic medicines sector. The company’s focus on in vivo gene editing, demonstrated through promising results such as sustained FVIII levels of 80% over 19 months in preclinical models, showcases its potential to address significant health conditions including Hemophilia A and cardiovascular diseases. This robust pipeline, combined with the strategic pursuit of technology licensing for ex vivo cell therapy, underscores a strong growth trajectory and long-term value proposition for investors.

Bears say

Metagenomi Therapeutics Inc reported a substantial net loss of $19.9 million for the second quarter of 2025, translating to a loss of $0.54 per share, which raises concerns regarding its financial sustainability. The company faces significant risks associated with potential delays in advancing its pipeline candidates through clinical assessments and the possibility of generating unfavorable clinical data, particularly for key programs such as Hemophilia A. Additionally, there are long-term dilution risks that may negatively impact shareholder value, contributing to a broader negative outlook for the stock.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.